17
Company presentation March, 2016
Company presentation March, 2016
7 « »
Company Overview
Biem Pharmaceuticals is
Pharmaceutical manufacturer with headquarters in
Ankara
Pharmaceutical marketing and distribution company
Proprietary portfolio of high-value branded
pharmaceutical products in Turkey
Global presence advancing in more than 11 countries
Committed to innovative solutions in Oncology,
Hematology, Radiology, Ophthalmology, Neurology
Founded
1989
Biem is founded
in 1989
1990
Biem becomes a
limited company
2012
Emaray & Pamiray is
launched
2014
Launch of Oncology
Portfolio
2015
Launch of Intensive
Care Portfolio
Biem becomes
Incorporated
Biem becomes exclusive
distributor of Cutter
2011
Until 2011 Biem is
distributor of Cutter, Miles
Bayer, Talecris
Organization
Board of Directors
General Manager Board of Directors
Consultant
Financial Director
Purchasing
Manager
Marketing and
Medical Director
Accountant HR
Manager
Warehouse
Manager
Warehouse
Officer
Warehouse
Responsible
Group
Manager
Tender
Officer Warehouse
officer TST
Product
Manager
Export Manager
Business D.
Officer
Export
Officer
Export
/İmport
Procuremen
t Officer
Statistic
Manager
P&P
Officer
Science
Responsible
Officer
Reg. Affairs
Officer
Regulatory
Affairs Manager
Satatistic
Responsible
ARGE
Officer
Mission, Vision & Strategy
Our Mission
Our Vision
to become the FIRST REMEDY
for saving lives by increasing life
quality with high tech, pioneering
products and
ONLY REMEDY able to provide
drugs produced with innovative
technology without pursuing high
profit margins, for illnesses that
affects only a small percentage of
the population
Our Strategy
to achieve growth in our
therapeutic field with an
innovative approach and
steady growth
always focused to produce the
best quality products, safe and
efficient, by searching innovative
solutions for happy and healthy
lifes
to increase the quality of our health services in all its activities,
while preserving the ethical values of the health industry
Biem as part of its strategy has accelerated its expansion
activities and products portfolio with a big focus on registration
sales, marketing and manufacturing on the domestic and
international pharmaceutical market.
Global Parteners
Biem has key partnership with leading Global Pharmaceutical companies:
Germany
Poland Italy
China
Korea India
International Business Worldwide
Biem’s Global
Network Azerbaijan Russia Georgia Albania Moldova Phillippines Kuwait Pakistan Chile Equador Colombia
Domestic Market:
a steady growth in the therapeutic market is
expected due to our ongoing portfolio.
International Market:
international business is increasing due to our
overseas sales activity through product registration
in more than 11 countries.
Countinuos Growth Strategy
$0
$1,000,000
$2,000,000
$3,000,000
$4,000,000
$5,000,000
$6,000,000
2012 2013 2014 2015 2016
$1,418,021
$2,031,802
$2,229,682
$3,639,576
$5,823,322
2012
2013
2014
2015
2016
60% growth targeted in 2016
Assests: 20.000.000 USD
Paid in Capital 6.500.000 USD
Product Portfolio
Biem portfolio consists of 27 human products, of which:
Radiocontrast Imaging 14.3%
Oncology 26.9%
Transplantology 10.7%
Intensive Care 21.4%
Opthalmology 28.6%
0.0%
Key moments 2012: launch of the Emaray and Pamiray
2014: launch of the Oncology and Ophthalmology Portfolio
2015: launch of the Intensive Care Portfolio
Product Portfolio: RADIOCONTRAST IMAGING
LOCAL PRODUCTS
Drug Name Active ingredient Treatment Area Launch date
EMARAY®
10,15,20 ml
Gadopentetate
dimeglumine
Magnetic Resonance imaging (MRI) 2012
PAMIRAY® 300/370
50,100 ml
Iopamidol CT Diagnostic imaging agent 2012
GADODIEM ®
287 mg/ml in 10,15,20 ml
Gadodiamide Magnetic Resonance imaging (MRI)
2015
BIEMEXOL® 300/350
50,100,200ml vials
Iohexol CT Diagnostic imaging agent 2015
Product Portfolio : HEMATO - ONCOLOGY
LOCAL PRODUCTS
Drug Name Registration
holder
Active
ingredient
Treatment Area Launch
date
BUSLERA®
6mg/ml
BIEM Busulfan Antineoplastic Agent / conditioning
treatment prior to conventional (HPCT)
2014
BEASTIN®
25mg /100 mg
BIEM Bendamustine
hydrochloride
Antineoplastics, Alkylating
agent/Chronic Lymphocytic Leukemia,
Non-Hodgkin Lymphoma,
2014
OCLADRA®
10mg/5ml
BIEM Cladribine Antineoplastics, Antimetabolite / Hairy
Cell Leukemia
2014
VOTRON®
250mcg/ml vial
BIEM Palonosetron Anti-vomiting and anti-
nausea/Chemotherapy side effects 2012
IMPORTED PRODUCTS
BIEMIB®3,5mg BIEM Bortezomib Mantle cell Lymphoma, Non-Hodgkin
Lymphomai Multiple Myeloma
2015
LETROKS®
2,5 mg tablet
Celon Farma Letrozol Antineoplastic agent/Breast cancer 2009
OXALIMEDAC®
50 mg/10 ml
100 mg/20 ml
Medac Oxaliplatine Antineoplastic agent/Colon cancer 2010
Product Portfolio: TRANSPLANTOLOGY
IMPORTED PRODUCTS
Drug Name Registration
holder
Active
ingredient
Treatment Area Launch date
PANOLIMUS®
0.5 /1/ 5 mg
capsules
PANACEA
BIOTEC.
Tacrolımus Organ and tissue
transplantology 2012
PANOSPORIN®
25/50/100 mg
capsules
PANACEA
BIOTEC.
Cyclosporıne Organ and tissue
transplantology;Dermatology
(psoriasis, athopic dermatitis
vs.)
2012
LOCAL PRODUCTS
EMFER®
100mg/5 ml
ampoules
BIEM Iron sucrose Haematinics (iron supplements) 2014
Product Portfolio: INTENSIVE CARE
LOCAL PRODUCTS
Drug Name Registration
holder
Active
ingredient
Treatment Area Launch Date
BIEMPARIN®
4mg/4ml
BIEM Heparine
sodium
Anticoagulant therapy 2016
SEDOZOLAM®
5mg/5ml, 15mg/3ml
BIEM Midazolam Anesthetic/Hypnotics/Sedative/Preoper
ative Sedation; 2016
BIEMEFRIN®
4mg/4ml
BIEM Norepinephrine Antihypotensives/Acute hypotension 2014
MRSACIN®
50mg
BIEM Tygecycline Antibiotic/Antibacterial for systemic use 2014
TROZASIN ®
200 mg/
BIEM Voriconazole Antifungal, Systemic/Invasive
aspergillosis; Nonneutropenic
candidemia;
2016
Product Portfolio: OPHTHALMOLOGY
IMPORTED PRODUCTS
Drug Name Registration holder Active ingredient Treatment Area Launch date
SICCAPROTECT® Ursapharm
Polyvinyl
alcohol+dexpanthenol
Artificial tears/Dry eyes
syndrome 2010
10 ml eye drops
VITAMIN A-POS ® Ursapharm Retinyl Palmitate
Vitamin/conjunctivitis
and atrophic change of
the cornea 2004
5 gr eye cream
FLUOROPOS®
Ursapharm Fluorometholone
Antiinflamation
agent/Steroid for
topical ophthalmic use 2005
5 ml eye drops
PREDNIPOS®
Ursapharm Prednisolon
Antiinflamation
agent/Steroid for
topical ophthalmic use 2007
10 ml eye drops
LOCAL PRODUCTS
ZARIDINEX ®
BIEM Ofloxacine
Anti-infective quinolone
antibiotics/bacterial eye
infection 2014
0,3% Ophthalmic
solution
ENFLUAT®
BIEM Ketorolac
tromethamine
Nonsteroidal anti-
inflammatory drug for
ophthalmic use 2014 0,4% Ophthalmic
solution
Future of BIEM
New Manufacturing Oncology Facility in Ankara
Future of BIEM
• Enable company to start business in US and European countries • Sustain a steady growth on the Turkish market by adding
innovative oncology products according standards • Established a new facility based on EU/ FDA GMP standards
1. Purpose of EU GMP/ FDA GMP standard facility
• Injection and Lyophilized: 120.000 units • Tablet: 14.000.000 units • Capsules: 410.000 units
2. Project Capacity Oncology Drugs Annualy
• Land Acquisition in Ankara Organized Industrial Zone 2: 18,000 m2
• 2015, September : Project Start
• 2016, August: Start Construction
• 2018, July : Complete Construction
3. Current Process
Development of innovative next generation oncology products to
expand domestic and global market share
Thank you Address:Turgut Reis Cad. No:21
Tandoğan/Ankara
Phone: (0312) 230 29 29
Fax: (0312) 230 68 00
